Skip to main content
Premium Trial:

Request an Annual Quote

Citigroup Lowers Illumina Revenue Forecast

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Citigroup today lowered revenue estimates for Illumina for the second quarter and for full-year 2011, saying that revenues from a trade-in program for the HiSeq 2000 next-generation sequencing platform would not be a "significant contributor" to total revenues.

Last year, Illumina launched a trade-in program offering customers the opportunity to trade in their Genome Analyzers for the new HiSeq 2000 system.

In a research note, analyst Amit Bhalla attributed the change in the estimate to anticipated lower revenues from Illumina's sequencing business, which he forecast at $97 million for the second quarter, down from the $105 million previously forecast.

He maintained a "Buy" rating on Illumina and a $90 target on the company's share price. His EPS estimate for the second quarter was also unchanged at $.38.

"We believe this will be a positive 2Q for Illumina as reduced trade-in volume should begin to materialize into gross margin expansion and investor attention focuses on the MiSeq launch in 2H11," Bhalla said.

For full-year 2011, he trimmed revenue estimates to $1.185 billion from $1.193 billion, and lowered the EPS estimate to $1.59 from $1.60. The full-year 2012 revenue estimate was lowered to $1.451 billion from $1.461 billion. Bhalla kept the EPS estimate at $2 for 2012.

Illumina is scheduled to report its second-quarter financial results on July 26.

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.